Top Stories
Bexlutry, equivalent to its reference product Lutathera, was approved for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs).
The biotech is proposing to sell 21.7 million shares at a range of $14 to $16 apiece.
Tambotatug pelitecan achieved a median overall survival of 13.3 months, reducing the risk of death by 54%.
The biotech is halting work on allogeneic CAR-T cell therapies in favour of in vivo base and epigenetic editing programmes
In the final OS analysis of the PAPILLON study, patients on Rybrevant plus chemotherapy lived a median 34.3 months versus 27.9 months with chemotherapy alone, which fell short of statistical significance.
Conference News
CPV-104 interim Phase 1 results support favorable safety and tolerability, with encouraging early efficacy trends in patients with C3 glomerulopathyDetailed interim Phase 1 data to be released in a vi...
HONG KONG, Sept. 15, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced the presentation of positive overall survival (OS) results from the randomized, double-blind, multicenter, registrationa...
Low rates of rash, blood clots and administration-related reactions were observed with subcutaneous treatment and prophylaxisFewer than 1% of patients discontinued treatment due to treatment-related e...
NANJING, China, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that updated Phase II data for opamtistomig (...
ARROS-1 data show durable systemic and intracranial activity, including a 100% intracranial response rate and a 70% intracranial complete response rateSEOUL, Republic of Korea, Sept. 14, 2026 /PRNewsw...
